Revolutionizing Urinary Tract Cancer Treatment: A Breakthrough in Dual ImmunotherapyRevolutionizing Urinary Tract Cancer Treatment: A Breakthrough in Dual Immunotherapy
Explore a groundbreaking international clinical trial that unveils a dual immunotherapy, enfortumab vedotin (EV) and pembrolizumab, extending patients’ life expectancy in late-stage urinary tract carcinoma. If approved, this marks a